WHO = World Health Organization has added the vaccine for the new coronavirus of China National Pharmaceutical Company China National Pharmaceutical to the list of emergency use and urged China National Pharmaceutical to cooperate with the international distribution framework.
WHO Executive Director Tedros announced on the 7th that it has added a vaccine developed by China's state-owned pharmaceutical company China National Pharmaceutical to its list of emergency use.
Vaccines developed by Western pharmaceutical companies such as Pfizer in the United States have been added to the list, but this is the first time outside the West.
As a result, China National Pharmaceutical's vaccine can be supplied to each country through the international distribution framework "COVAX Facility" led by WHO and others, and WHO requested China National Pharmaceutical to cooperate with COVAX.
COVAX relies on vaccines developed by AstraZeneca and Oxford University, which are manufactured in India, for more than 70% of the vaccines to be distributed by next month, but the supply is large due to the worsening infection situation in India. I'm late for
WHO wants to accelerate the distribution of vaccines to developing countries by adding China National Pharmaceutical's list of vaccines.
The severe situation of COVAX
In February, the COVAX Facility, a framework for fair distribution of vaccines led by the World Health Organization, announced plans to distribute more than 300 million doses of vaccines to 145 countries and regions around the world by next month. did.
However, COVAX was able to distribute more than 54 million vaccines to 121 countries and regions by the 7th, which is significantly behind the original plan.
COVAX relies on vaccines developed by AstraZeneca and Oxford University, which are manufactured at factories in India, for more than 70% of the vaccines to be distributed by next month, but due to the worsening infection situation in India, Supply to COVAX is stagnant.
In an attempt to catch up, COVAX announced on the 3rd of this month that it had signed a contract to receive 500 million doses of vaccine from American pharmaceutical company Moderna, but the supply is expected to begin later this year.
WHO is reviewing the efficacy and safety of vaccines developed around the world to increase the types of vaccines that can be distributed by COVAX, to see if they can be added to the list of emergency use.